[Evidence-based treatment of psychosis associated with Parkinson's disease].

Abstract

Psychotic symptoms in Parkinson's disease are frequent phenomena and are often associated with an immense burden for caregivers, increased risk of nursing home placement and mortality. Treatment of psychotic disorders associated with Parkinson's disease often poses a therapeutic dilemma and necessitates a differentiated risk-benefit assessment as both the reduction of antiparkinsonian drugs and use of antipsychotic drugs can result in deterioration of motor functions. This article gives an overview of relevant clinical aspects and highlights the pharmacological evidence-based treatment options.

• Authors: R Haussmann, M Bauer, M Donix
• Journal: Der Nervenarzt (Nervenarzt) Vol. 87 Issue 5 Pg. 543-51 (May 2016) ISSN: 1433-0407 [Electronic] Germany
• Vernacular Title: Evidenz zur Behandlung der Parkinson-assoziierten Psychose.
• PMID: 26643499 (Publication Type: Journal Article)

Chemical References

• Antiparkinson Agents
• Antipsychotic Agents

Topics

• Antiparkinson Agents (adverse effects, therapeutic use)
• Antipsychotic Agents (adverse effects, therapeutic use)
• Dementia (diagnosis, drug therapy)
• Evidence-Based Medicine
• Germany
• Guideline Adherence
• Homes for the Aged
• Humans
• Nursing Homes
• Parkinson Disease (diagnosis, drug therapy)
• Psychotic Disorders (diagnosis, drug therapy)
• Risk Assessment